4. Overview of Johnson & Johnson
A Broadly Based Health Care
Company
Johnson & Johnson is the world’s most
comprehensive and broadly based
manufacturer of health care products and
services for the consumer, pharmaceutical,
and medical & diagnostics markets.
The Corporation achieved this leadership by
concentrating on a unique form of
decentralized management, following the
ethical principles embodied in our Credo and
managing the business for the long term.
5. Overview
• Headquartered in New Brunswick, NJ
• Companies in 57 countries, selling products in
more than 175 countries
• 2011 sales were US$ 65 billion
• Over 110,600 employees worldwide
• Extensive worldwide research and supply
chain capabilities
• More than US$280 million pa philanthropy
6. Founded in 1886.
Founded by :
ROBERT WOOD-1
JAMES WOOD JOHNSON
EDWARD MEAD JPHNSON
7. This is the illustration of the fist building of johnson &
johnson company
This factory was been set up beside the railroad
By 1907 , J&J expanded from a single building to 35 buildings .
By the same year 2500 employees were working .
8. Robert Wood Johnson-1 :1887-1910
James Wood Johnson :1910-1932
Robert Wood Johnson-2 :1932-1963
Philip B. Hofmann :1963-1973
Richard B. Sellars :1973-1976
James E. Burke :1976-1989
Ralph S. Larsen :1989-2002
William C. Weldon :2002-
9. Mission/Vision Statement
Johnson & Johnson, a global
company, posts that "The fundamental
objective of Johnson & Johnson is to
provide scientifically sound, high
quality products and services to help
heal, cure disease and improve the
quality of life."
10. Sales Results By Segment
Pharmaceutical
47
Medical %
Devices & 35
Diagnostic % 17
%
Consumer
11. Consumer Health Care
• Skin care
• Baby care
• Wound care
• Oral care
• Over-the-
Counter-Drugs
and Vitamins
12. Medical Devices & Diagnostics
• Diabetes
• Ortho-clinical
• Chordis
• Depuy
• Vision care
14. RoC® BRILLIANCE
Starts working immediately to
reduce the appearance of dark
circles and puffiness and is
clinically proven to smooth and
tighten the look of delicate skin
around the eyes.
NEUTROGENA Rapid Clear® Sore
Pimple Gel
Instantly cools to soothe sore
pimples and clinically proven to
reduce the size, redness and
swelling of sore pimples in just 8
hours.
15. Competitors
Abbott Laboratories:
Abbott laboratories is engaged in discovery,
development, manufacture and sale of a
variety of health care products through four
business segments: Pharmaceutical,
Diagnostics, Nutritional and Vascular products.
• Merck & Co. Inc.:
A top competitor is Merck & Co. which offers
treatment and medication four adults and
children over a wide range of application.
Merck has a strong position in the world of
pharmaceutical with such advancements as
Gardasil, the world first anticancer vaccine,
Diabetes medication eye disease treatment
and multiple Cardio Vascular drugs such as
Cozaar and Hyzaar.
16. • Novartis:
Novartis offer over 60 pharmaceutical products
including one of the most well known drugs,
ritalin, and has received more approvals than
any other pharmaceutical company in the
industry since 2000
• Pfizer:
Pfizer has tow segments: Pharmaceutical, which
develops and produces products that treat
cardio vasular and metabolic diseases, central
nervous system disorders, cancer, eye disease
etc. and Animal Health, which disvovers,
develops and sells products for the prevention
and treatment of diseases in livestock and
companion animals.
17. STRATEGIES
• Strategic Acquisitions
Johnson & Johnson has maintained a stable
financial position by utilizing cash reserves to
finance timely corporate acquisitions. Its’ Triple
–A Credit Rating represents a company able to
take advantage of opportunities that arise
without being limited by burdensome levels of
debt.
18. Product Diversification
The Johnson & Johnson pharmaceutical portfolio,
and ts large Medical Devices & Diagnostics (M,D
&D) and Consumer Health divisions serves to
reduce dependence upon any one area. The
company plans to continue this broadening
through 2008-14. This diversification allows a
wider range of choice when pursuing opportunities
with the greatest growth prospects.
19. Positive Revenue
Growth Projections
The potential of an impressive number of new product
launches and the promise of achieving forecast
sales is said to bode well for Johnson & Johnson,
helping it weather the recent decline in
prescription pharmaceuticals and projecting a turn-
around through 2010. An increase at 1.8% CAGR
across 2008–14 is believed to be achievable.
21. SWOT Analysis
• Strengths:
• Broad diversity of products. Not reliant on a sole
product line for majority of revenue.
• Repeat customers. People tend to be brand-loyal.
If they buy Tylenol for their headaches, they tend
to repeatedly buy Tylenol.
• Strong brands. "No more tears" shampoo, Band-
Aid, Tylenol, Visine, etc.
• Generally smart purchasing of companies. For
instance, it didn't purchase
22. WEAKNESS
• A conglomerate of relatively independent
companies. Sometimes they can go off the
reservation, such as what appears to have
happened with McNeil Consumer Healthcare and
the making of the children's medicine now being
recalled.
• Several of its big drugs have lost or will soon lose
patent protection.
• Many of its products are commodities. For
instance, other adhesive bandages exist, not just
Band-Aid.
OPPORTUNITIES
• Development of personalized drugs that work best
on specific genetic profiles, such as Gleevec
from Novartis
• Continued smart purchasing of companies with
complementary products.
23. THREATS
• Increasing pressure to move to generic drugs.
• Stiff competition instants, especially from Abbott
Labs , Boston Scientific, and Medtronic , and
having to keep one step ahead of everyone else.
25. Future
• Over the past two decades, Johnson & Johnson
has continued to set and meet a series of long-
term targets across a range of environmental
impacts – including Pollution Prevention Goals,
Next Generation Goals, and its most recently
completed Healthy Planet 2010 Goals.. The next
step in its evolution was to go bolder and broader
with Healthy Planet 2015 Goals..
At the heart of Healthy Planet 2015 Goals are 15
of the boldest and broadest sustainability goals we
have set to date and extend well beyond
environmental stewardship to include an emphasis
on improving people’s health, increasing corporate
transparency and encouraging collaborative
partnerships.
